Paroxetin in the treatment of depressive and anxio-fobic disorders in bronchial asthma patients
Abstract
W e performed an opened, uncontrolled study of therapeutic efficacy, safety and tolerability of the psychotropic drug paroxetin (Paxil) in 25 patients with bronchial asthma (BA) and depressive (DD) or anxlity disorders (AD). The patients’ group involved 7 males and 18 females aged 34 to 61 years. All the patients received the antiasthmatic therapy according to the severity of the disease. Paroxetin was taken in the daily dose of 20 mg for 6 weeks. The patients’ status was evaluated with the HADS scale; the reduction of this parameter by 50% and more was considered as an efficacy criterion. The safety and tolerability of the drug were assessed using pneumotachometry and adverse events were evaluated with the UKU scale. The study results showed the paroxetin is well-tolerated (only 3 patients drop out from the study dure to dyspeptic syndrome) and an effective drug for DD and AFD in BA patients. The airway obstruction parameters were significantly increased under the combined treatment with paroxetin and anti-asthmatic medication.
About the Authors
M. Yu. Drobizhev
отдел по изучению пограничной психической патологии и психосоматических расстройств НЦ ПЗ РАМН
Russian Federation
Russian Federation
S. I. Ovcharenko
Кафедра внутренних болезней № 1 ММА им. И.М.Сеченова
Russian Federation
Russian Federation
E. N. Ishchenko
межклиническос психосоматическое отделение клиники кардиологии ММА им. И.М.Сеченова
Russian Federation
Russian Federation
O. V. Vishnevskaya
Кафедра внутренних болезней № 1 ММА им. И.М.Сеченова
Russian Federation
Russian Federation
K. A. Baturin
отдел по изучению пограничной психической патологии и психосоматических расстройств НЦ ПЗ РАМН
Russian Federation
Russian Federation
N. A. Tokareva
Кафедра внутренних болезней № 1 ММА им. И.М.Сеченова
Russian Federation
Russian Federation
References
1. Дроздов Д.В., Аллилуев И.Г., Полтавская М.Г. Применение психотропных препаратов и возможности лекарственных взаимодействий у кардиологических больных. В кн.: Смулевич А.Б., Сыркин А.Л. (ред.) Психические расстройства и сердечно-сосудистая патология. М.; 1994. 101-112.
2. Спивак Д.И., Райский В.А., Виленский B.C. Осложнения психофармакологической терапии. Л.; 1988.
3. Binkley K.E., Kutcher S. Panic response to sodium lactate infusion in patients with multiple chemical sensitiv
4. Cazzola M., Matera M.G. 5-HT modifiers as a potential treatment. TiPS 2000; 21: 13-16.
5. Dirks J.F., Schraa J.C., Brown E. Psychomaintenance in asthma: hospitalisation rates and financial impact. Br. J. Med. Psychol. 1980; 53: 349-354.
6. Dupont L.J., Pype J.L., Demedts M.G. et at. The effects of 5-HT on cholinergic contraction in human airways in vitro. Eur. Respir. J. 1999; 14(3): 642-649.
7. Hyland M.E., Kenyon C.A., Allen R., Howarth P. Diary keeping in asthma: comparison of written and electronic methods. Br. Med. J. 1993; 306(6876): 487-489.
8. Lingaerde O., Ahlfors U.G., Bech P. et al. The UKU side effect rating scale. A new comprehensive rating sacale for psychotropic drugs and cross-sectional study of side effects in neuroleptictreated patients. Acta Psychiatr. Scand. 1987; suppl.334: 1 — 100.
9. Moran M. The anxiety of asthma: emotions can trigger attack. Recognizing psychological triggers can help master disease, http://my.webmd.ca/content/article/1728.79155
10. Reuters Health. Paroxetine therapy improves premenstrual asthma. Toronto, May 10, 2000 http://www.helphorizons.com/vo/default.asp
11. Rubin N.J. Severe asthma and depression. Arch. Fam. Med. 1993: 2: 4433-4440.
12. Sperber A.D. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf. 1991; 6(6): 460-462.
13. Stahl S.M. Essential psychopharmacology of depression and bipolar disorder. Cambridge: Cambridge university press; 2000.
14. Stoudemire A., Moran M.G., Fogel B.S. Psychotropic drug use in the medically ill: Part I. Psychosomatics 1990; 31 (4): 377-391.
15. Taylor C.B., Hayward C. Cardiovascular considerations in selection of anti-panic pharmacotherapy. J. Psyhosom. Res. 1990; 24 (suppl.2): 496-497.
16. Wamboldt M.Z., Yancey A.G., Jr., Roesler T.A. Cardiovascular effects of tricyclic antidepressants in childhood asthma: a case series and review. J. Child Adolesc. Psychopharmacol. 1997; 7(1): 45-64.
17. Yellowlees P.M., Alpers J.H., Bowden J.J. et al. Psychiatric morbidity in-patients with chronic airflow obstruction. Med. J. Aust. 1987; 146: 305-307.
18. Yellowlees P.M., Haynes S., Potts N., Ruffin R.E. Psychiatric morbidity in patients with life-threatening asthma: initial report of a controlled study. Ibid. 1988; 149: 246-249.
19. Zigmont A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67: 361-370.
Review
For citations:
Drobizhev M.Yu., Ovcharenko S.I., Ishchenko E.N., Vishnevskaya O.V., Baturin K.A., Tokareva N.A. Paroxetin in the treatment of depressive and anxio-fobic disorders in bronchial asthma patients. PULMONOLOGIYA. 2002;(3):96-100. (In Russ.)
Views:
573
Email this article 